26 feb: Prospekt Februar 2019
27 feb: TCM Group A/S: Årsrapport 2018
26-02-2019 13:43:58

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

Copenhagen, Denmark; February 26, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 26,297 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

140 shares at DKK 40.41,

750 shares at DKK 45.24,

750 shares at DKK 66.60,

1,000 shares at DKK 68.65,

320 shares at DKK 79.25,

250 shares at DKK 80.55,

10,000 shares at DKK 174.00,

2,400 shares at DKK 220.40,

1,950 shares at DKK 225.30,

1,500 shares at DKK 231.50,

5,250 shares at DKK 234.00,

1,187 shares at DKK 337.40,

50 shares at DKK 466.20, and

750 shares at DKK 636.50.

Proceeds to the company are approximately DKK 5.39 million. The increase corresponds to approx. 0.043 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2018. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No 12 of January 8, 2018, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 61,523,868, which is made up of 61,523,868 shares of a nominal value of DKK 1 each, corresponding to 61,523,868 votes.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 09

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
21 maj - 
Aktier/åbning: Demant og Genmab til tops i grønt marked
13 maj - 
Aktier/middag: Ambu bankes ned i rødt marked
10 maj - 
De mest shortede aktier i april – Pandora kravler op af..
Relateret debat
23 maj - 
Jo, teknologien (UltimAb) var som sådan valideret, så e..
23 maj - 
Dengang var der ingen bevis for den succes teknologien ..
23 maj - 
Præcis, der kommer højst sandsynigt ikke en bud på biks..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
23 maj
GEN
Novartis har 25 blockbustere i pipelinen og milliarder på vej til Genmab AF MARTIN HAVTORN PETERSEN ..
5
20 maj
GEN
Men for at svare på dit spørgsmål vedr. kort og langsigtet vil vi se den brage op igennem taget kort..
4
20 maj
GEN
Vi kan forvente os milepælsbetalinger og synes det er værd at bemærke denne:Eksempelvis estimerede a..
3
21 maj
GEN
Det lugter af en godkendelse lige om hjørnet....
2
20 maj
GEN
Nu er "brage op igennem taget" og "voldsom stigning" jo relativ. Hvad er voldsom stigning - 10 % ? D..
2
20 maj
GEN
Godt skrevet spekulanten89. Jeg er 100% enig. Har også et million beløb i Genmab.. Langsigtet.
2
23 maj
GEN
JNJ kan købe daratumumab ud for 1750... Så kører vi videre med resten... 😀
1
23 maj
GEN
Tja Genmab vil være i sigtekornet for opkøb så langt øjet rækker.
1
23 maj
GEN
Og den her skal da også med:https://medwatch.dk/secure/Medicinal___Biotek/article11368278.ece?fbclid..
1
22 maj
GEN
Den skal lige presses op over 1200, det er et psykologisk stærkt tal så mon ikke vi kan se 1210 idag..
1

Ny storaktionær i DSV: Schweizisk finansgigant har købt op

23-05-2019 16:10:20
Den schweiziske finansgigant UBS er blevet storaktionær i den danske transportkoncern DSV.Det fremgår af en meddelelse fra DSV torsdag.- UBS Group har meddelt, at det har har erhvervet aktier og finansielle instrumenter i DSV, hvilket har bragt den direkte og indirekte ejerandel over 5 pct., fremgår det af meddelelsen.Samlet råder UBS over en ejerandel i DSV på 6,10 pct. af den samlede aktiekapita..

Tyske PMI-tal offentliggjort: "Landets afgørende industrisektor halter stadig"

Relaterede nyheder
23-05-2019 10:42:42
PMI-barometeret over indkøbschefernes syn på aktiviteten i Tyskland udviklede sig overordnet set som ventet i majs foreløbige opgørelse.Tallene var på ingen måde prangende, lyder vurderingen fra Frederik Engholm, der er chefstrateg hos Nykredit.- Det tyske PMI-indeks for fremstillingssektoren viser, at landets afgørende industrisektor stadig halter. Indekset er tæt på uændret - falder fra 44,4 til..

Scandinavian Tobacco Group fremlægger flot regnskab

23-05-2019 08:22:40
En gunstig valutaudvikling og et tidligere opkøb har i årets første tre måneder været med til at løfte resultaterne hos Scandinavan Tobacco Group (STG), der samtidig holder fast i forventningerne til indeværende regnskabsår.Koncernomsætningen endte i første kvartal på 1464 mio. kr., hvilket var mere end de 1285 mio. kr., som omsætningen landede på i samme kvartal sidste år. Det fremgår af kvartals..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Pandora bundprop i cyklisk nedtur for rødt C25
2
Aktier/tendens: Regnskaber i fokus i ventet rød start
3
Torsdagens aktier: Mærsk til tælling inden kvartalstal i surt marked
4
Ny storaktionær i DSV: Schweizisk finansgigant har købt op
5
Svinepriser på himmelflugt giver lettelse hos landmænd - og banker

Relaterede aktiekurser

Genmab A/S 1.199,50 -0,3% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2019 05:13:27
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190514.2 - EUROWEB2 - 2019-05-24 05:13:27 - 2019-05-24 05:13:27 - 1 - Website: OKAY